<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99142">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01909258</url>
  </required_header>
  <id_info>
    <org_study_id>AOI/2012/PK</org_study_id>
    <secondary_id>2013-A00232-43</secondary_id>
    <nct_id>NCT01909258</nct_id>
  </id_info>
  <brief_title>Pelvic Area Extension Measurements for Four Types of Lumbopelvic Balance Using Three Different Methods</brief_title>
  <acronym>CRESPEOS</acronym>
  <official_title>Comparison and Reproducibility of Pelvic Area Extension Measurements for Four Types of Lumbopelvic Balance Using Three Different Methods: Clinical Observation Versus Photography Versus the EOS Imaging System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to describe for the first time the expansion reserve of
      the pelvic area (measurements using the EOS system) for each of the four morphotypes
      (Roussouly classification) commonly found in a population of healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>EOS measurement of intrinsic reserve extension = angular variation of the sacral slope</measure>
    <time_frame>baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
    <description>= RIEeos</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EOS measurement of extrinsic extension reserve</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
    <description>= REEeos = angular variation of a specific angle (line joining the center of the sacral plate and the midpoint of the segment involving the center of the femoral head and the line joining this point to the top of the intercondylar knee notch )</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EOS measurement of global extension reserve</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
    <description>= RIEeos + REEeos</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Goniometric measurement of global extension reserve</measure>
    <time_frame>baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Photographic measurement of global extension reserve</measure>
    <time_frame>baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Roussouly classification: 1, 2, 3 or 4</measure>
    <time_frame>baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic incidence (°)</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pelvic Incidence is defined as the angle between two lines: the line perpendicular to the sacral endplate at the middle of the sacral endplate to the line between the middle of the sacral endplate to the middle of the femoral heads.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standing sacral slope</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standing pelvic release</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standing anterior pelvic plane</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The front acetabular inclination while standing</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The sagittal acetabular inclination while standing</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>The study population.</arm_group_label>
    <description>Healthy volunteers 20 to 30 years of age.
Intervention: Goniometric measure of pelvic extension reserve. Intervention: Photographic measure of pelvic extension reserve. Intervention:  EOS measure of pelvic extension reserve.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Goniometric measure of pelvic extension reserve.</intervention_name>
    <description>The pelvic extension reserve (°) is measured via goniometry.</description>
    <arm_group_label>The study population.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Photographic measure of pelvic extension reserve.</intervention_name>
    <description>The pelvic extension reserve (°) is measured using photography.</description>
    <arm_group_label>The study population.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EOS measure of pelvic extension reserve.</intervention_name>
    <description>The pelvic extension reserve (°) is measured using the imaging system EOS.</description>
    <arm_group_label>The study population.</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy volunteers 20 to 30 years of age.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The healthy volunteer must have given his/her informed and signed consent

          -  The healthy volunteer must be insured or beneficiary of a health insurance plan

        Exclusion Criteria:

          -  The healthy volunteer is participating in another study

          -  The healthy volunteer is in an exclusion period determined by a previous study

          -  The healthy volunteer is under judicial protection, under tutorship or curatorship

          -  The healthy volunteer refuses to sign the consent

          -  It is impossible to correctly inform the healthy volunteer

          -  The healthy volunteer is pregnant, parturient, or breastfeeding

          -  The healthy volunteers had a history of chronic pain or surgery at the hip, the
             thoracolumbar spine or the sacroiliac area

          -  The healthy volunteer has a hip, knee or ankle abnormality
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal Kouyoumdjian, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pascal Kouyoumdjian, MD, PhD</last_name>
    <phone>+33.(0)4.66.68.72.92</phone>
    <email>pascal.kouyoumdjian@chu-nimes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carey Suehs, PhD</last_name>
    <phone>+33.(0)4.66.68.67.88</phone>
    <email>carey.suehs@chu-nimes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Montpellier - Hôpital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Catherine Cyteval, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Vialla, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 9</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pascal Kouyoumdjian, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gérard Asencio, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Remy Coulomb</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Paul Beregi, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique Blin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 3, 2014</lastchanged_date>
  <firstreceived_date>July 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
